FI20165814A - INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY - Google Patents
INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPYInfo
- Publication number
- FI20165814A FI20165814A FI20165814A FI20165814A FI20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A
- Authority
- FI
- Finland
- Prior art keywords
- interleukin
- prognostic
- oncolytic
- proudic
- biomarker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Abstract
The present invention relates to an oncolytic viral vector comprising a nucleic acid sequence encoding an anti-interleukin 8 neutralizing antibody.Further, the present invention relates to use of interleukin 8 as a prognostic and predictive biomarkerin oncolytic immunotherapy. In this respect, the present invention is directed to a method ofanalysing whether a subject suffering from a cancer is responsive or non-responsive to the treatment with an oncolytic viral vectorand to a method of monitoringefficacy of an oncolytic immunotherapy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20165814A FI20165814A (en) | 2016-10-27 | 2016-10-27 | INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY |
PCT/FI2017/050742 WO2018078220A1 (en) | 2016-10-27 | 2017-10-27 | Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20165814A FI20165814A (en) | 2016-10-27 | 2016-10-27 | INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY |
Publications (1)
Publication Number | Publication Date |
---|---|
FI20165814A true FI20165814A (en) | 2018-04-28 |
Family
ID=60569934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20165814A FI20165814A (en) | 2016-10-27 | 2016-10-27 | INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY |
Country Status (2)
Country | Link |
---|---|
FI (1) | FI20165814A (en) |
WO (1) | WO2018078220A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102089121B1 (en) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Oncolytic adenovirus compositions |
CN117384961A (en) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics |
AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
MX2021005525A (en) * | 2018-11-12 | 2021-06-18 | Aptarion Biotech Ag | Cxcl8 binding nucleic acids. |
CN111363726A (en) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | Oncolytic virus expressing interferon and application thereof |
SG11202110697UA (en) * | 2019-03-28 | 2021-10-28 | Mayo Found Medical Education & Res | Ifnbeta as a pharmacodynamic marker in vsv-ifnbeta-nis oncolytic therapy |
EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030096781A1 (en) * | 2001-08-31 | 2003-05-22 | University Of Southern California | IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma |
AU2003299641C1 (en) | 2002-12-16 | 2016-06-02 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US9345787B2 (en) * | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
SG188550A1 (en) * | 2010-09-24 | 2013-04-30 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
US20150266961A1 (en) * | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
KR101458947B1 (en) | 2013-03-05 | 2014-11-12 | 국립암센터 | Interleukin-8 aptamers and uses thereof |
WO2014170389A1 (en) | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
SG11201707541WA (en) | 2015-03-17 | 2017-10-30 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
-
2016
- 2016-10-27 FI FI20165814A patent/FI20165814A/en not_active Application Discontinuation
-
2017
- 2017-10-27 WO PCT/FI2017/050742 patent/WO2018078220A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018078220A1 (en) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20165814A (en) | INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY | |
EA201891001A1 (en) | VACCINES ON THE BASIS OF NUCLEIC ACIDS AGAINST WINDSHEAD VIRUS (VZV) | |
MX2017014125A (en) | Alpha-amylase variants and polynucleotides encoding same. | |
BR112017013981A2 (en) | anti-cll1-specific chimeric single-chain antigen receptors (sccars) for cancer immunotherapy | |
MX2017006216A (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als). | |
EP3741849A3 (en) | Protease variants and polynucleotides encoding same | |
BR112017009728A2 (en) | isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder | |
WO2016196975A8 (en) | Neutralizing antibodies to hiv-1 env and their use | |
BR112016013347A2 (en) | anti-il-33 neutralizing human monoclonal antibody | |
EA201792080A1 (en) | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF THEIR APPLICATION | |
EA201892417A1 (en) | ANTIBODIES RECOGNIZING TAU | |
MX2018008051A (en) | Beta-glucanase variants and polynucleotides encoding same. | |
WO2015013388A3 (en) | Anti-galectin-1 monoclonal antibodies and fragments thereof | |
MX2019000140A (en) | Xylanase variants and polynucleotides encoding same. | |
EA201892412A1 (en) | ANTIBODIES RECOGNIZING TAU | |
NZ758093A (en) | Monoclonal antibody to pd-l1 | |
PE20190415A1 (en) | HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE OF THEM | |
MX2019013370A (en) | Optimized nucleic acid antibody constructs. | |
MX2016013849A (en) | A protein secretory factor with high secretory efficiency and an expression vector comprising the same. | |
PH12018501070A1 (en) | Anti-pcsk9 antibody and use thereof | |
BR112018001202A2 (en) | monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method | |
BR112016021679A2 (en) | antigen binding protein, methods of producing an antigen binding protein and identifying one or more antigen binding proteins, hybridoma, nucleic acid, cell, and genetically modified non-human animal. | |
EA201890351A1 (en) | RECOMBINANT ORF-VIRAL VECTOR | |
PH12016501579B1 (en) | Novel anti-presepsin antibody | |
TN2017000066A1 (en) | Anti-vasa antibodies, and methods of production and use thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |